TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00426647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Study: NCT01741948

Intervention type: DRUG
Intervention: Hormonal contraceptive
Description: The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy.
Study: NCT03776786

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo
Study: NCT02281877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: 5x/week, 2x/day, for 45 minutes/session
Study: NCT04200612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Psychotherapy
Description: Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
Study: NCT02281877

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: Standard physical therapy after TKA
Study: NCT04200612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Equine-Assisted Activities
Description: Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activities
Description: Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
Study: NCT02281877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Protocol
Description: Standard physical therapy after TKA
Study: NCT01191749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
Study: NCT05219890

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
Study: NCT00183898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine
Description: cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
Study: NCT01227811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Single oral dose Darisec(R) 15.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: Single oral dose Enablex(R) 15 mg
Study: NCT00694746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters
Description: Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
Study: NCT02119000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG/electrolytes 2L/2L split dose
Description: Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose
Description: Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes
Study: NCT01651585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir arrow
Description: dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
Study: NCT02741817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
Study: NCT02943759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem leaf extract
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
Study: NCT00408954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UK-369,003
Description: 100 mg MR tablet once daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UK-369,003
Description: UK-369,003-100 mg MR formulation for 2 weeks
Study: NCT04217356

Intervention type: BIOLOGICAL
Intervention: Hematopoietic stem cell transplant
Description: Intravenous infusion of hematopoietic stem cells from a donor.

Intervention type: DRUG
Intervention: Ruxolitinib
Description: Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).

Intervention type: DRUG
Intervention: Hydroxyurea
Description: Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
Study: NCT03620279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magic camp intervention
Description: Hand-arm bimanual motor skills training
Study: NCT01254877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: ondansetron 0.2 mg bid, oral preparation, 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ondansetron
Description: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
Study: NCT02440867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS
Description: Sham stimulation
Study: NCT02529332

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
Study: NCT00303953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study: NCT01909271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Education Film Viewing
Description: A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.

Intervention type: OTHER
Group type: OTHER
Intervention: Stroke Education Pamphlet Exposure
Description: Usual Care: Stroke Education pamphlet and brochure distribution.
Study: NCT03510000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single hormone artificial pancreas
Description: Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal strategies
Description: Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
Study: NCT03695835

Intervention type: DRUG
Intervention: Immunotherapeutic Agents
Description: Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

Intervention type: DEVICE
Intervention: Ablation
Description: Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
Study: NCT03692962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Time in bed will be restricted to 5 hours per night for 7 nights.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep restriction
Description: Time in bed will be restricted to 5 hours per night for 7 nights.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Description: Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
Study: NCT03669471

Intervention type: OTHER
Intervention: Testing of performance
Description: The cross-sectional evaluation will involve assessment of:~1. Hip muscle function~2. Single leg jump performance~3. Self-reported hip and groin function~4. Evaluation of return to sport~5. Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk.
Study: NCT03737019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education with Acceptance and Commitment Therapy
Description: Group education with Acceptance and Commitment Therapy of the personnel at each center.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, no intervention
Description: Control, no interventions.
Study: NCT04235075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG/PCG and ultrasound signal acquisition
Description: The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants.
Study: NCT03509155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National portion & IYCF counseling
Description: Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjusted portion & local food counseling
Description: four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
Study: NCT00287820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: olanzapine 5-40 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 5-40 ,mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone 1-12 mg/day
Study: NCT02617095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2762
Description: One drop in each eye 3 to 6 times daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: One drop in each eye 3 to 6 times daily
Study: NCT04324840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Specified dose on specified days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified days

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Specified dose on specified days
Study: NCT04032223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placemet in the mandibular canine regions
Description: Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placemet in the mandibular canine regions
Description: Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
Study: NCT01910441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1-6 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (1000-1500 mg daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin (1000-1500 mg daily)
Study: NCT02691338

Intervention type: OTHER
Intervention: EEG
Description: EEG analysis

Intervention type: OTHER
Intervention: EEG
Description: EEG analysis

Intervention type: OTHER
Intervention: Routine follow up tests
Description: Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
Study: NCT03060928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Rotator Cuff Repair
Description: Arthroscopic Rotator Cuff Repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Rotator Cuff Repair
Description: Arthroscopic Rotator Cuff Repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Rotator Cuff Repair
Description: Arthroscopic Rotator Cuff Repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-perforations
Description: Biological stimulation with micro-perforations
Study: NCT01315821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 months
Study: NCT01891045

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OQ-45.2 no feedback
Description: Completion of the OQ-45.2 before each session, but no feedback to therapists or patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OQ-45.2
Description: Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
Study: NCT00663949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: 25 mg captopril tablet q8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril + Pentoxifylline
Description: patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
Study: NCT03060928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-perforations
Description: Biological stimulation with micro-perforations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artelon®
Description: Biological stimulation with Artelon® Tissue Reinforcement
Study: NCT02896842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posology dose modification
Study: NCT04200612

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-control group
Description: This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
Study: NCT02415309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg Melatonin
Description: 40 patients will randomly receive 2 mg melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Melatonin
Description: 40 patients will randomly receive 10 mg melatonin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 patients will randomly receive a placebo/sugar pill
Study: NCT05426148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
Description: The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
Description: The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
Description: The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
Study: NCT02220387

Intervention type: OTHER
Intervention: exposure to respirable silica dust
Description: History of exposure to respirable silica dust due to job

Intervention type: OTHER
Intervention: exposure to polycyclic aromatic hydrocarbons exhaust
Description: history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
Study: NCT02747784

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training program RehaCom®
Description: Cognitive training program RehaCom®

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program RehaCom®
Description: Cognitive training program RehaCom®